SLNO
NASDAQSoleno Therapeutics Inc.
Price$53.02+12.93 (+32.27%)
2026-02-112026-05-15
News · 26 weeks96+282%
2025-12-072026-05-31
Mix6390d
- SEC Filings30(48%)
- Other16(25%)
- Insider15(24%)
- Earnings1(2%)
- Dividends1(2%)
Latest news
25 items- SECSEC Form 15-12G filed by Soleno Therapeutics Inc.15-12G - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form EFFECT filed by Soleno Therapeutics Inc.EFFECT - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form POS AM filed by Soleno Therapeutics Inc.POS AM - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form AW filed by Soleno Therapeutics Inc.AW - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- INSIDEROfficer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERDirector Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERDirector Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERDirector Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERChief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERChief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERChief Development Officer Joshi Manher returned 20,171 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERSr. VP of Clinical Development Huang Michael F. returned 39,823 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDEROfficer Hirano Patricia C returned 22,702 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERDirector Hahn Mark W returned 10,046 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Fulk Jennifer returned 39,200 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERDirector Bir Dawn Carter returned 16,991 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Anish Bhatnagar returned 583,656 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
- SECSEC Form S-8 POS filed by Soleno Therapeutics Inc.S-8 POS - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form S-8 POS filed by Soleno Therapeutics Inc.S-8 POS - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form S-8 POS filed by Soleno Therapeutics Inc.S-8 POS - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form S-8 POS filed by Soleno Therapeutics Inc.S-8 POS - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form S-8 POS filed by Soleno Therapeutics Inc.S-8 POS - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form S-8 POS filed by Soleno Therapeutics Inc.S-8 POS - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form S-8 POS filed by Soleno Therapeutics Inc.S-8 POS - SOLENO THERAPEUTICS INC (0001484565) (Filer)
- SECSEC Form S-8 POS filed by Soleno Therapeutics Inc.S-8 POS - SOLENO THERAPEUTICS INC (0001484565) (Filer)
SLNO FAQ
7 questionsWhat does Soleno Therapeutics Inc. do?
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation...Where does SLNO stock trade?
Soleno Therapeutics Inc. (SLNO) is listed on NASDAQ.What sector and industry is SLNO in?
Soleno Therapeutics Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did Soleno Therapeutics Inc. go public?
Soleno Therapeutics Inc. (SLNO) completed its IPO in 2014.What are analysts saying about SLNO?
Soleno Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2025-11-18.What companies are similar to SLNO?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare SLNO side-by-side with any of them on Quantisnow.How can I track SLNO on Quantisnow?
Quantisnow aggregates Soleno Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLNO to receive live email and push alerts on every new disclosure.